Related Experiment Video
Updated: Jun 12, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Gene therapy for human ovarian cancer cells using efficient expression of Fas gene combined with γδT cells
Jiajing Lin1, Dingyuan Zeng2, Hongying He1
1Department of Gynecology, The 4th Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China.
Abstract:
Low tissue specificity and efficiency of exogenous gene expression are the two major obstacles in tumor‑targeted gene therapy. The Fas cell surface death receptor (Fas)/Fas ligand pathway is one of the primary pathways responsible for the regulation of cell apoptosis. The aim of the present study was to explore whether the regulation of tumor specific promoters and a two‑step transcriptional amplification system (TSTA) assured efficient, targeted expression of their downstream Fas gene in human ovarian cancer cells, and to assess the killing effect of γδT cells on these cells with high Fas expression. Three shuttle plasmids containing different control elements of the human telomerase reverse transcriptase (hTERT) promoter and/or TSTA were constructed and packaged into adenovirus 5 (Ad5) vectors for the expression of exogenous Fas gene. The human ovarian cancer cell line SKOV3 and a control human embryonic lung fibroblast cell line were transfected with Ad5‑hTERT‑Fas or Ad5‑hTERT‑TSTA‑Fas. Fas mRNA and protein expression were examined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. γδT lymphocytes were isolated, cultured and mixed at different ratios with SKOV3 cells with Fas expression in order to assess the killing effect of γδT cells. hTERT promoter induced the specific expression of FAS gene in SKOV3 cells, and the TSTA strategy increased FAS expression by 14.2‑fold. The killing effect of γδT cells increased with the expression level of Fas and the effector‑target cell ratio. The killing rate for SKOV3 cells with high FAS expression was 72.5% at an effector‑target cell ratio of 40:1. The regulators of hTERT promoter and TSTA assure the efficient and targeted expression of their downstream Fas gene in SKOV3 cells. The killing effect of γδT cells for ovarian cancer cells with relatively high Fas expression was improved.
Insights
This study demonstrates that the human telomerase reverse transcriptase (hTERT) promoter and a two-step transcriptional amplification (TSTA) system can efficiently target and enhance Fas gene expression in ovarian cancer cells. This improved Fas expression significantly boosts the cancer-killing ability of gamma delta T (γδT) cells.
Area of Science:
- Gene Therapy
- Oncology
- Immunotherapy
Background:
- Tumor-targeted gene therapy faces challenges with low tissue specificity and inefficient exogenous gene expression.
- The Fas/Fas ligand pathway is crucial for regulating apoptosis, making it a target for cancer treatment.
- Enhancing Fas expression in cancer cells can increase their susceptibility to immune-mediated killing.
Purpose of the Study:
- To investigate the efficacy of tumor-specific promoters and a two-step transcriptional amplification (TSTA) system for targeted Fas gene expression in human ovarian cancer.
- To evaluate the enhanced killing effect of gamma delta T (γδT) cells on ovarian cancer cells with upregulated Fas expression.
Main Methods:
- Construction of adenovirus 5 (Ad5) vectors containing the Fas gene under the control of the human telomerase reverse transcriptase (hTERT) promoter, with or without TSTA.
- Transfection of human ovarian cancer cells (SKOV3) and control cells with the constructed Ad5 vectors.
- Assessment of Fas gene and protein expression using RT-qPCR and Western blot.
- Evaluation of γδT cell-mediated cytotoxicity against Fas-expressing SKOV3 cells at various effector-target ratios.
Main Results:
- The hTERT promoter specifically induced Fas gene expression in SKOV3 ovarian cancer cells.
- The TSTA strategy significantly amplified Fas expression, achieving a 14.2-fold increase.
- γδT cell-mediated killing of SKOV3 cells increased proportionally with Fas expression levels and effector-target cell ratios, reaching 72.5% at a 40:1 ratio.
Conclusions:
- The combination of the hTERT promoter and TSTA system effectively achieves targeted and efficient exogenous Fas gene expression in ovarian cancer cells.
- Upregulation of Fas expression enhances the susceptibility of ovarian cancer cells to γδT cell-mediated lysis, offering a promising strategy for ovarian cancer therapy.
More Related Videos
07:40Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery
Published on: May 16, 2018
06:51Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling
Published on: August 6, 2025
Related Concept Videos
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy